Danish pharmaceutical giant Novo Nordisk and U.S. biotech Septerna agreed to collaborate on the development of pills to treat obesity, type 2 diabetes and other metabolic conditions. Under the ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

COPENHAGEN (Reuters) -Novo Nordisk (NVO) has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 weight-loss drug in the form of an oral pill. Septerna's stock is ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...